Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.

Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。